A new trading day began on Friday, with Phathom Pharmaceuticals Inc (NASDAQ: PHAT) stock price down -6.15% from the previous day of trading, before settling in for the closing price of $19.50. PHAT’s price has ranged from $6.07 to $19.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -42.48%. With a float of $37.51 million, this company’s outstanding shares have now reached $57.97 million.
Let’s determine the extent of company efficiency that accounts for 452 employees. In terms of profitability, gross margin is 82.86%, operating margin of -2548.78%, and the pretax margin is -2995.67%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 45.07%, while institutional ownership is 47.62%. The most recent insider transaction that took place on Jul 15 ’24, was worth 127,760. In this transaction Chief Operating Officer of this company sold 10,901 shares at a rate of $11.72, taking the stock ownership to the 240,421 shares. Before that another transaction happened on Jul 15 ’24, when Company’s CFO and CBO sold 4,325 for $11.72, making the entire transaction worth $50,689. This insider now owns 99,447 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -42.48% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Here are Phathom Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 125.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.13, a number that is poised to hit -1.47 in the next quarter and is forecasted to reach -4.41 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 1.01 million, which is a jump from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 86.79%. Additionally, its Average True Range was 1.02.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 87.43%, which indicates a significant increase from 77.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.91% in the past 14 days, which was higher than the 62.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.27, while its 200-day Moving Average is $10.27. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $19.25. Second resistance stands at $20.20. The third major resistance level sits at $20.73. If the price goes on to break the first support level at $17.77, it is likely to go to the next support level at $17.24. Should the price break the second support level, the third support level stands at $16.29.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
With a market capitalization of 1.25 billion, the company has a total of 58,535K Shares Outstanding. Currently, annual sales are 680 K while annual income is -201,590 K. The company’s previous quarter sales were 7,320 K while its latest quarter income was -91,450 K.
